Blocking the interaction between PD1 and PDL1 has been of revolutionary significance in cancer therapy, resulting in approvals for PD1/PDL1 blocking agents from the US Food and Drug Administration (FDA) for the treatment of several cancers [50]. This evidence concerns the gene CD274 and cancer.